Venugopal, B. and Evans, T.R.J. (2011) Gemcitabine elaidate cytotoxic agent oncolytic. Drugs of the Future, 36(6), pp. 427-432.
Full text not currently available from Enlighten.
Publisher's URL: http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=1608941&p_IsPs=N
Abstract
Cemcitabine is an established chemotherapeutic agent for the treatment of a variety of malignancies, including pancreatic, bladder, breast and non-small cell lung cancers. Cemcitabine requires specialized nucleoside transporters, which facilitate its entry into cells, and there is a growing body of evidence suggesting that these nucleoside transporters play a key role in gemcitabine sensitivity. Gemcitabine elaidate (CP- 4126, gemcitabine-5'-elaidic ester), is a novel cytotoxic agent that permeates the cell membrane independent of nucleoside transporters. A phase I trial of CP-4126 in patients with solid malignancies has shown promising antitumor activity. In this review, we discuss the origin, mechanism of action, preclinical and clinical evidence of antitumor activity of this novel drug.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Venugopal, Dr Balaji and Evans, Professor Jeff |
| Authors: | Venugopal, B., and Evans, T.R.J. |
| Subjects: | R Medicine > RM Therapeutics. Pharmacology |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
| Journal Name: | Drugs of the Future |
| ISSN: | 0377-8282 |
University Staff: Request a correction | Enlighten Editors: Update this record
Deposit and Record Details
Deposit and Record Details